Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Meta unveils Quest 3 mixed reality headset ahead of Apple's VR debut
EA Sports FC 24 Evolutions Expert Objective: How to Complete
Xbox Brazil recalls Final Fantasy 7 Remake ad that hinted at game coming to Xbox
Biden says there is need to address security, economic risks posed by AI
Annual Paramount+ plans (including the Showtime bundle) are 50% off
How to Participate in the Modern Warfare 3 Live Event
20 of the best free artificial intelligence courses on edX
The best home security cameras for privacy and peace of mind